JP2005529160A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005529160A5 JP2005529160A5 JP2004509679A JP2004509679A JP2005529160A5 JP 2005529160 A5 JP2005529160 A5 JP 2005529160A5 JP 2004509679 A JP2004509679 A JP 2004509679A JP 2004509679 A JP2004509679 A JP 2004509679A JP 2005529160 A5 JP2005529160 A5 JP 2005529160A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- group
- alkyl
- phenyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 178
- 125000000217 alkyl group Chemical group 0.000 claims 63
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 54
- 125000001188 haloalkyl group Chemical group 0.000 claims 45
- 125000001072 heteroaryl group Chemical group 0.000 claims 43
- 150000002825 nitriles Chemical class 0.000 claims 40
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 40
- 229910052736 halogen Inorganic materials 0.000 claims 39
- 150000002367 halogens Chemical class 0.000 claims 39
- 150000001875 compounds Chemical class 0.000 claims 35
- 125000000753 cycloalkyl group Chemical group 0.000 claims 34
- 239000003814 drug Substances 0.000 claims 30
- 125000001424 substituent group Chemical group 0.000 claims 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 24
- 125000003545 alkoxy group Chemical group 0.000 claims 23
- 125000005842 heteroatom Chemical group 0.000 claims 22
- 229910052760 oxygen Inorganic materials 0.000 claims 19
- 229910052717 sulfur Inorganic materials 0.000 claims 19
- 206010012601 diabetes mellitus Diseases 0.000 claims 18
- 229940079593 drug Drugs 0.000 claims 14
- -1 hydroxy, amino Chemical group 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 12
- 239000008177 pharmaceutical agent Substances 0.000 claims 11
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 10
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 10
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 239000008103 glucose Substances 0.000 claims 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 8
- 125000004076 pyridyl group Chemical group 0.000 claims 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 8
- 125000001544 thienyl group Chemical group 0.000 claims 8
- 229940122199 Insulin secretagogue Drugs 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000002541 furyl group Chemical group 0.000 claims 6
- 125000002883 imidazolyl group Chemical group 0.000 claims 6
- 125000002098 pyridazinyl group Chemical group 0.000 claims 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims 6
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 5
- 108090001061 Insulin Proteins 0.000 claims 5
- 229940122355 Insulin sensitizer Drugs 0.000 claims 5
- 229940126033 PPAR agonist Drugs 0.000 claims 5
- 229940100389 Sulfonylurea Drugs 0.000 claims 5
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 5
- 230000003579 anti-obesity Effects 0.000 claims 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 230000029142 excretion Effects 0.000 claims 5
- 229940125396 insulin Drugs 0.000 claims 5
- 210000004185 liver Anatomy 0.000 claims 5
- BNYHRGTXRPWASY-UHFFFAOYSA-N nonylsulfonylurea Chemical compound CCCCCCCCCS(=O)(=O)NC(N)=O BNYHRGTXRPWASY-UHFFFAOYSA-N 0.000 claims 5
- 125000002971 oxazolyl group Chemical group 0.000 claims 5
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 230000000580 secretagogue effect Effects 0.000 claims 5
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 5
- 125000000335 thiazolyl group Chemical group 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 201000001421 hyperglycemia Diseases 0.000 claims 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 3
- 201000008980 hyperinsulinism Diseases 0.000 claims 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 229940030600 antihypertensive agent Drugs 0.000 claims 2
- 239000002220 antihypertensive agent Substances 0.000 claims 2
- 229920000080 bile acid sequestrant Polymers 0.000 claims 2
- 229940096699 bile acid sequestrants Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940125753 fibrate Drugs 0.000 claims 2
- 208000004104 gestational diabetes Diseases 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229960003512 nicotinic acid Drugs 0.000 claims 2
- 235000001968 nicotinic acid Nutrition 0.000 claims 2
- 239000011664 nicotinic acid Substances 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 102100040918 Pro-glucagon Human genes 0.000 claims 1
- 102100037505 Secretin Human genes 0.000 claims 1
- 108010086019 Secretin Proteins 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960004580 glibenclamide Drugs 0.000 claims 1
- 229960001381 glipizide Drugs 0.000 claims 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229950004994 meglitinide Drugs 0.000 claims 1
- 229960000698 nateglinide Drugs 0.000 claims 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229960002354 repaglinide Drugs 0.000 claims 1
- 229960002101 secretin Drugs 0.000 claims 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38459502P | 2002-05-31 | 2002-05-31 | |
| PCT/US2003/017193 WO2003101988A2 (en) | 2002-05-31 | 2003-05-30 | Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005529160A JP2005529160A (ja) | 2005-09-29 |
| JP2005529160A5 true JP2005529160A5 (https=) | 2006-06-29 |
Family
ID=29712061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004509679A Withdrawn JP2005529160A (ja) | 2002-05-31 | 2003-05-30 | 糖尿病及び糖尿病−関連障害の処置のための化合物及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1513840B1 (https=) |
| JP (1) | JP2005529160A (https=) |
| AU (1) | AU2003273192A1 (https=) |
| CA (1) | CA2482345A1 (https=) |
| DE (1) | DE60308862T2 (https=) |
| ES (1) | ES2274268T3 (https=) |
| WO (1) | WO2003101988A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007004781A (es) * | 2004-10-20 | 2007-05-11 | Applied Research Systems | Derivados de 3-arilamino piridina. |
| WO2013178320A1 (en) * | 2012-05-30 | 2013-12-05 | Merck Patent Gmbh | Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1022214A (en) * | 1963-01-31 | 1966-03-09 | Sterling Drug Inc | Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation |
| JP3242792B2 (ja) * | 1994-08-05 | 2001-12-25 | 日本臓器製薬株式会社 | ナフチリジニウム誘導体 |
| KR100567649B1 (ko) * | 1996-09-25 | 2006-04-05 | 아스트라제네카 유케이 리미티드 | 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체 |
-
2003
- 2003-05-30 ES ES03756326T patent/ES2274268T3/es not_active Expired - Lifetime
- 2003-05-30 CA CA002482345A patent/CA2482345A1/en not_active Abandoned
- 2003-05-30 EP EP03756326A patent/EP1513840B1/en not_active Expired - Lifetime
- 2003-05-30 JP JP2004509679A patent/JP2005529160A/ja not_active Withdrawn
- 2003-05-30 WO PCT/US2003/017193 patent/WO2003101988A2/en not_active Ceased
- 2003-05-30 AU AU2003273192A patent/AU2003273192A1/en not_active Abandoned
- 2003-05-30 DE DE60308862T patent/DE60308862T2/de not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006212761B2 (en) | Combination therapy | |
| JP2006516251A5 (https=) | ||
| CA3093851A1 (en) | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same | |
| RU2006134004A (ru) | Производные гетероариламинопиразола, пригодные для лечения диабета | |
| JP2004528334A5 (https=) | ||
| US20110280831A1 (en) | Combinations comprising methotrexate and dhodh inhibitors | |
| JP2010516715A5 (https=) | ||
| SG192439A1 (en) | Organic compounds | |
| JP2004536115A5 (https=) | ||
| JP2010524953A5 (https=) | ||
| RU2012101095A (ru) | Диарилтиогидантоиновые соединения | |
| WO2016149111A1 (en) | Treating latent autoimmune diabetes of adults with farnesoid x receptor agonists to activate intestinal receptors | |
| CN101622229A (zh) | 具有脲基和氨基羰基作为取代基的新型吡咯衍生物 | |
| JP2005526696A5 (https=) | ||
| JP2006510728A5 (https=) | ||
| JP2024515062A (ja) | 重水素化ｄｈｏｄｈ阻害剤 | |
| RU2004129285A (ru) | Производные тиазола в качестве антагонистов рецептора npy | |
| CN105916522A (zh) | 用于治疗神经变性疾病的新方法 | |
| JP2005529160A5 (https=) | ||
| JP2008530242A5 (https=) | ||
| WO2024012496A1 (zh) | 大麻素受体化合物及其用途 | |
| JP2007538054A5 (https=) | ||
| EP2668951B9 (en) | 1,2,4-oxadiazole derivatives as drugs modulating the glp-1 peptide receptor | |
| JP2007538102A5 (https=) | ||
| WO2024102455A1 (en) | Non-covalent inhibitors of coronavirus main protease |